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As we are in the middle of an unprecedented outbreak of
obesity in the world, the role of the gut microbiota and its
manipulation need to be investigated and our area of study
needs to be involved in the process. Since 2006 [1] a link has
been established between the composition of the gut micro-
biota and obesity. This has highlighted that the Firmicutes to
Bacteroidetes ratio of the gut is different depending on the body
weight and on the diet of people. Moreover, the transplantation
of the gut microbiota from obese humans or mice to xenobiotic
mice consistently modiﬁes the mouse metabolism and induces a
tendency to develop diabetes as well as a metabolic syndrome
[2]. Data are accumulating that show that the gut microbiota
repertoire is linked with both obesity and diet. The recent link
observed between obesity and the composition of the human
gut microbiota raises the hypothesis that the antibiotics and
probiotics that manipulate the gut microbiota and that have
been used in the farming industry as growth promoters for
decades, may also cause weight gain in humans [3].
Antibiotics are still being used in the USA by the farming
industry to promote weight gain in livestock. The same effect
has been found in a recent study in laboratory mice receiving
low doses of antibiotics (penicillin and vancomycin) and who
subsequently showed weight and adiposity gain [4]. The
composition of the mouse microbiota was changed during
treatment. Interestingly there was a signiﬁcant increase of
Lactobacillales in the fecal samples of the antibiotic-treated
mice. Another study has found that children receiving
antibiotics before the age of 3 months are bigger than
others [5]. In adult humans, some studies show weight gain
following treatment with vancomycin [6]. For years, an
equivalent to vancomycin was used as a growth promoter in
farm animals, under the name of Avoparcin. Interestingly
these compounds are active against most gram-positive
bacteria except for some Lactobacillus species [6]. Finally,
there is evidence that patients with prolonged antibiotic
treatment for Helicobacter pylori infections [7] or cystic
ﬁbrosis (either using azithromycin or clarithromycin) may
experience weight gain [8].
Probiotics, speciﬁcally some Lactobacillus species can also
cause weight gain in farm animals [9]. They are commonly used
as growth promoters in Europe, where antibiotics are no
longer allowed [3,10]. A study on mice, after ingestion of
Lactobacillus ingluviei, has identiﬁed weight gain, an abnormal
glucidic response and signiﬁcant changes in the microbiota
composition [11]. There is now congruent evidence that some
probiotics have a similar effect and promote weight gain among
young children [9]. A meta-analysis has shown that several
species have a speciﬁcally higher potential as growth promot-
ers in human and animals: L. ingluviei, Lactobacillus fermentans,
Lactobacillus acidophilus and perhaps Lactobacillus reuteri. Some
of these species are present in large numbers in some food or
functional food marketed for humans [12]. Interestingly many
Lactobacillus species secrete compounds with antibiotic activ-
ities [12]. Clearly, there is a link between antibiotic and
probiotic activities.
Overall, this new ﬁeld, combining obesity and gut microbi-
ota manipulation, requires more investment from our ﬁeld.
Whenever possible, these studies need to be independent
from the pharmaceutical companies and from the food
industry to avoid biases of publications reporting [13]. In
practice, we need to investigate the consequences of antibiotic
treatments on our patients’ weight. We need to investigate if
probiotics added to the diets of young children play a role in
obesity. We also need to develop scientiﬁc studies in
collaboration with specialists in obesity. In the current issue,
this journal is proposing a thematic approach comprising ﬁve
reviews devoted to this topic: ‘Gut Bacterial Microbiota and
Obesity’ by Mical et al. [14], ‘Lessons from farm industry/
probiotics’ by Vernoux and Bernardeau [15], ‘Obesity, non-
alcoholic fatty liver disease and atherothrombosis: a role for
the intestinal microbiota?’ by Nieuwdorp et al. [16] and ‘Gut
microbiota and non alcoholic fatty liver disease: new insights’
by Dutour et al. [17]. This link created between clinical
microbiology and obesity may be very fruitful.
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